Nan Fung Life Sciences
Nan Fung Life Sciences a global life sciences investment platform with a long-term capital commitment from the Nan Fung Group.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Nan Fung Life Sciences Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Linkedin
Crunchbase
Metrics
4,022,497Website Global Rank
2,966Website Monthly Traffic
Twitter Followers
Description
Nan Fung Life Sciences are a global life sciences investment platform with a long-term capital commitment from the Nan Fung Group. Our team possesses diverse experience with long track records in company formation, venture capital, growth/buyout investments, and drug discovery and development. Through direct investments via Pivotal bioVenture Partners US and Pivotal bioVenture Partners China as well as fund investments, we cover the full spectrum of the life sciences industry including therapeutics, medical devices and diagnostics and across all development stages.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 11/2021 | Ablaze Pharmaceuticals | Series A | 0 |
| 6/2020 | Engrail Therapeutics | Series A | 32M |
| 5/2018 | Fountain Therapeutics | Series A | 5M |
| 12/2021 | DermBiont | Series A | 0 |
| 10/2017 | Eargo | Series C | 45M |
| 6/2019 | OncXerna Therapeutics | Series B | 80M |
| 7/2020 | Arctic Vision | Series A | 0 |
| 1/2021 | Encodia | Series C | 75M |
| 3/2021 | Arctic Vision | Series B | 0 |
| 2/2020 | Fountain Therapeutics | Series A | 6M |
| 5/2021 | Oculis | Series C | 0 |
| 12/2017 | Aptinyx | Series B | 70M |
| 7/2018 | Omniome | Series B | 0 |
| 11/2021 | Fountain Therapeutics | Series A | 0 |
| 1/2018 | SomaLogic | Venture Round | 0 |
| 7/2020 | Eargo | Series E | 0 |
| 9/2018 | Galera Therapeutics | Series C | 70M |
| 6/2018 | OncXerna Therapeutics | Seed Round | 16.5M |
| 1/2019 | Oculis | Series B | 15.7M |
| 10/2017 | Harmony Biosciences | Venture Round | 0 |
| 1/2020 | Omniome | Series C | 60M |
| 8/2021 | Engrail Therapeutics | Series A | 32M |
| 3/2019 | Eargo | Series D | 52M |
| 2/2019 | Bolt | Series B | 54M |
| 12/2021 | DermBiont | Series A | 0 |
| 11/2021 | Ablaze Pharmaceuticals | Series A | 0 |
| 11/2021 | Fountain Therapeutics | Series A | 0 |
| 8/2021 | Engrail Therapeutics | Series A | 0 |
| 5/2021 | Oculis | Series C | 0 |
| 3/2021 | Arctic Vision | Series B | 0 |
| 1/2021 | Encodia | Series C | 0 |
| 7/2020 | Eargo | Series E | 0 |
| 7/2020 | Arctic Vision | Series A | 0 |
| 6/2020 | Engrail Therapeutics | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
